Avidity Biosciences Inc
RNA72.900USD
+0.080+0.11%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
10.70BMarket Cap
LossP/E TTM
More Details of Avidity Biosciences Inc Company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Avidity Biosciences Inc Info
Ticker SymbolRNA
Company nameAvidity Biosciences Inc
IPO dateJun 12, 2020
CEOBoyce (Sarah)
Number of employees391
Security typeOrdinary Share
Fiscal year-endJun 12
Address3020 Callan Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18584017900
Websitehttps://www.aviditybiosciences.com/
Ticker SymbolRNA
IPO dateJun 12, 2020
CEOBoyce (Sarah)
Company Executives of Avidity Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
139.31K
-270218.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
80.09K
+30634.00%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
32.30K
-44627.00%
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Distinguished Scientist and Strategic Leader, Director
Distinguished Scientist and Strategic Leader, Director
--
--
Mr. Michael F. (Mike) Maclean
Mr. Michael F. (Mike) Maclean
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
--
-6692.00%
Dr. Noreen Roth Henig, M.D.
Dr. Noreen Roth Henig, M.D.
Independent Director
Independent Director
--
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
--
-6692.00%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
--
-6692.00%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
139.31K
-270218.00%
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
80.09K
+30634.00%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
32.30K
-44627.00%
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Distinguished Scientist and Strategic Leader, Director
Distinguished Scientist and Strategic Leader, Director
--
--
Mr. Michael F. (Mike) Maclean
Mr. Michael F. (Mike) Maclean
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
12.47M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.00%
The Vanguard Group, Inc.
8.80%
Wellington Management Company, LLP
6.50%
T. Rowe Price Associates, Inc.
6.24%
RA Capital Management, LP
5.58%
Other
59.88%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.00%
The Vanguard Group, Inc.
8.80%
Wellington Management Company, LLP
6.50%
T. Rowe Price Associates, Inc.
6.24%
RA Capital Management, LP
5.58%
Other
59.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.70%
Investment Advisor/Hedge Fund
34.65%
Venture Capital
6.72%
Hedge Fund
6.24%
Corporation
3.28%
Research Firm
2.48%
Private Equity
1.49%
Sovereign Wealth Fund
0.64%
Individual Investor
0.47%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
579
151.27M
97.78%
-9.44M
2025Q3
513
144.57M
99.88%
-1.36M
2025Q2
498
141.72M
117.38%
-3.41M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
20.11M
13.35%
+4.29M
+27.11%
Sep 30, 2025
The Vanguard Group, Inc.
13.19M
8.76%
+3.97M
+42.98%
Sep 30, 2025
Wellington Management Company, LLP
10.07M
6.68%
+815.50K
+8.82%
Sep 30, 2025
T. Rowe Price Associates, Inc.
9.65M
6.41%
-1.02M
-9.54%
Sep 30, 2025
RA Capital Management, LP
8.64M
5.73%
+1.38M
+18.92%
Sep 30, 2025
Janus Henderson Investors
14.52M
9.64%
+2.39M
+19.71%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
5.25%
-268.89K
-3.29%
Sep 30, 2025
Avoro Capital Advisors LLC
7.64M
5.07%
+595.00K
+8.44%
Sep 30, 2025
Bristol Myers Squibb
5.08M
3.37%
--
--
Sep 30, 2024
State Street Investment Management (US)
4.89M
3.24%
+687.12K
+16.35%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Return Stacked Bonds & Merger Arbitrage ETF
11.96%
Global X Genomics & Biotechnology ETF
7.84%
ALPS Medical Breakthroughs ETF
4.27%
State Street SPDR S&P Biotech ETF
3.4%
ProShares Merger ETF
2.74%
Direxion Daily S&P Biotech Bull 3X Shares
1.82%
Virtus LifeSci Biotech Clinical Trials ETF
1.47%
AltShares Event-Driven ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.12%
Invesco Nasdaq Biotechnology ETF
0.87%
View more
Return Stacked Bonds & Merger Arbitrage ETF
Proportion11.96%
Global X Genomics & Biotechnology ETF
Proportion7.84%
ALPS Medical Breakthroughs ETF
Proportion4.27%
State Street SPDR S&P Biotech ETF
Proportion3.4%
ProShares Merger ETF
Proportion2.74%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.82%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.47%
AltShares Event-Driven ETF
Proportion1.46%
ProShares Ultra Nasdaq Biotechnology
Proportion1.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.87%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
